Co-Diagnostics (NASDAQ: CODX) prices $3M private placement with warrants
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Co-Diagnostics, Inc. entered into a private placement to raise approximately $3.0 million in gross proceeds from institutional and accredited investors. The company is selling 54,915 common shares, pre-funded warrants for 1,592,532 shares, and common warrants for 3,294,894 shares, primarily for general corporate purposes and working capital.
The securities are priced at a combined $1.821 per share (or pre-funded warrant) and accompanying warrants, with common warrants exercisable at $1.571 per share for five years. Company insiders agreed to 60-day lock-ups, and Co-Diagnostics committed to file a resale registration statement and observe temporary restrictions on additional and variable-rate financings.
Positive
- None.
Negative
- None.
Insights
Co-Diagnostics raises $3.0M via a warrant-heavy private placement that brings cash in but adds potential dilution.
Co-Diagnostics is raising approximately $3.0 million in gross proceeds through a private placement of equity and warrants priced at-the-market under Nasdaq rules. The structure combines 54,915 common shares, 1,592,532 pre-funded warrants, and 3,294,894 common warrants, all immediately exercisable.
The transaction includes a 7% cash fee to Maxim Group and a $50,000 expense reimbursement, plus registration rights that require filing a resale statement within 15 days of May 19, 2026. Lock-ups on officers, directors, and restrictions on variable-rate deals temporarily limit additional equity issuance.
Overall this looks like a routine small-cap capital raise: it brings in modest funding for general corporate and working capital needs, while creating future warrant overhang. Actual impact on ownership will depend on how many of the pre-funded and common warrants are ultimately exercised.
8-K Event Classification
4 items: 1.01, 3.02, 8.01, 9.01
4 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Private placement gross proceeds: $3.0 million
Common shares issued: 54,915 shares
Pre-funded warrants: 1,592,532 shares
+5 more
8 metrics
Private placement gross proceeds
$3.0 million
Aggregate gross proceeds from private placement
Common shares issued
54,915 shares
New common stock in private placement
Pre-funded warrants
1,592,532 shares
Shares underlying pre-funded warrants
Common warrants
3,294,894 shares
Shares underlying 5-year common warrants
Combined offering price
$1.821 per unit
Per share (or pre-funded warrant) plus accompanying warrants
Warrant exercise price
$1.571 per share
Exercise price of common warrants
Placement agent fee
7.0% of gross proceeds
Cash fee payable to Maxim Group LLC
Expense reimbursement
$50,000
Reimbursement of Maxim’s reasonable expenses
Key Terms
Private Placement, Pre-Funded Warrants, Common Warrants, Registration Rights Agreement, +2 more
6 terms
Private Placement financial
"entered into a private placement transaction (the “Private Placement”), pursuant to a Securities Purchase Agreement"
A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.
Pre-Funded Warrants financial
"pre-funded warrants to purchase 1,592,532 shares of Common Stock (the “Pre-Funded Warrants”)"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Common Warrants financial
"warrants to purchase 3,294,894 shares of Common Stock (the “Common Warrants”)"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
Registration Rights Agreement financial
"pursuant to a Registration Rights Agreement (the “Registration Rights Agreement”) entered into with the Purchasers"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
Rule 144 financial
"have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Beneficial Ownership Limitations financial
"A holder will not have the right to exercise any portion of the Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99%"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
FAQ
What did Co-Diagnostics (CODX) announce in this 8-K filing?
Co-Diagnostics announced a private placement financing to raise about $3.0 million in gross proceeds. The deal combines newly issued common shares, pre-funded warrants, and common warrants sold to institutional and accredited investors for general corporate purposes and working capital.
What are the pricing terms of the Co-Diagnostics (CODX) private placement?
Each common share (or pre-funded warrant) plus accompanying warrants is priced at a combined $1.821. The common warrants carry an exercise price of $1.571 per share and are exercisable immediately for five years, providing investors long-dated upside exposure to Co-Diagnostics’ equity.
How will Co-Diagnostics (CODX) use the $3.0 million raised?
Co-Diagnostics plans to use the net proceeds from the approximately $3.0 million private placement for general corporate purposes and working capital. This broad language typically covers operating expenses, product development, and other routine corporate funding needs as determined by management.
What lock-up and issuance restrictions are tied to the Co-Diagnostics (CODX) deal?
Officers and directors agreed not to sell or transfer company securities for 60 days after closing. Co-Diagnostics also agreed not to issue additional equity or variable-rate securities for periods of 60 days and 90 days, respectively, following the defined effective date milestone.
What registration rights did Co-Diagnostics (CODX) grant investors?
The company agreed to file a resale registration statement within 15 days of May 19, 2026, targeting effectiveness within 30 days of filing, or 60 days if fully reviewed. Co-Diagnostics will keep this registration effective until all covered securities can be sold or rely on Rule 144.